XML 107 R30.htm IDEA: XBRL DOCUMENT v3.25.3

Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Operations by Reportable Segment

Approximate information concerning the Company’s operations by reportable segment for the three and nine months ended September 30, 2025 and 2024 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein:

Schedule of Operations by Reportable Segment 

Three Months Ended September 30, 2025		Product Packaging				Commercial Lending				Direct Marketing				Biotechnology				Securities				Corporate				Total
Revenue		$	4,935,000			$	7,000			$	-			$	11,000			$	1,439,000			$	-			$	6,392,000
Cost of revenue			4,380,000				(192,000	)			-				12,000				1,868,000				-				6,068,000
Gross profit (loss)			555,000				199,000				-				(1,000	)			(429,000	)			-				324,000
Operating expense			894,000				57,000				(7,587,000	)			883,000				(1,754,000	)			11,065,000				3,558,000
Operating income (loss)			(339,000	)			142,000				7,587,000				(884,000	)			1,325,000				(11,065,000	)			(3,234,000	)
Other income (expense)			(35,000	)			370,000				(21,000	)			3,000				609,000				79,000				1,005,000
Net income (loss) from operations before taxes			(374,000	)			512,000				7,566,000				(881,000	)			1,934,000				(10,986,000	)			(2,229,000	)

Three Months Ended September 30, 2024		Product Packaging				Commercial Lending				Direct Marketing				Biotechnology				Securities				Corporate				Total
Revenue		$	4,846,000			$	45,000			$	-			$	1,000			$	707,000			$	-			$	5,599,000
Cost of revenue			4,350,000				252,000				(2,000	)			10,000				1,993,000				-				6,603,000
Gross profit (loss)			496,000				(207,000	)			2,000				(9,000	)			(1,286,000	)			-				(1,004,000	)
Operating expense			766,000				104,000				73,000				1,169,000				901,000				654,000				3,667,000
Operating income (loss)			(270,000	)			(311,000	)			(71,000	)			(1,178,000	)			(2,187,000	)			(654,000	)			(4,671,000	)
Other income (expense)			(43,000	)			251,000				(52,000	)			(573,000	)			336,000				(949,000	)			(1,030,000	)
Net income (loss) from operations before taxes			(313,000	)			(60,000	)			(123,000	)			(1,751,000	)			(1,851,000	)			(1,603,000	)			(5,701,000	)

Nine Months Ended September 30, 2025		Product Packaging				Commercial Lending				Direct Marketing				Biotechnology				Securities				Corporate				Total
Revenue		$	13,221,000			$	37,000			$	-			$	32,000			$	3,340,000			$	-			$	16,630,000
Cost of Revenue			12,274,000				20,000				(7,000	)			36,000				4,430,000				-				16,753,000
Gross profit (loss)			947,000				17,000				7,000				(4,000	)			(1,090,000	)			-				(123,000	)
Operating expense			2,357,000				197,000				(7,519,000	)			3,124,000				(855,000	)			12,957,000				10,261,000
Operating income (loss)			(1,410,000	)			(180,000	)			7,526,000				(3,128,000	)			(235,000	)			(12,957,000	)			(10,384,000	)
Other income (expense)			(110,000	)			(46,000	)			(22,000	)			49,000				(318,000	)			677,000				230,000
Net income (loss) from operations			(1,520,000	)			(226,000	)			7,504,000				(3,079,000	)			(553,000	)			(12,280,000	)			(10,154,000	)

Nine Months Ended September 30,2024		Product Packaging				Commercial Lending				Direct Marketing				Biotechnology				Securities				Corporate				Total
Revenue		$	11,466,000			$	192,000			$	3,000			$	2,000			$	2,018,000			$	-			$	13,681,000
Cost of revenue			10,715,000				719,000				(2,000	)			30,000				5,804,000				-				17,266,000
Gross profit (loss)			751,000				(527,000	)			5,000				(28,000	)			(3,786,000	)			-				(3,585,000	)
Operating expense			2,313,000				338,000				227,000				2,637,000				3,023,000				2,164,000				10,702,000
Operating income (loss)			(1,562,000	)			(865,000	)			(222,000	)			(2,665,000	)			(6,809,000	)			(2,164,000	)			(14,287,000	)
Other income (expense)			(118,000	)			(73,000	)			134,000				(699,000	)			52,000				(934,000	)			(1,638,000	)
Net loss from operations			(1,680,000	)			(938,000	)			(88,000	)			(3,364,000	)			(6,757,000	)			(3,098,000	)			(15,925,000	)

Schedule of Disaggregation of Revenue

The following tables disaggregate our business segment revenues by major source:

 Schedule of Disaggregation of Revenue

Printed Products Revenue Information:  

Three months ended September 30, 2025
Packaging Printing and Fabrication		$	4,841,000
Commercial and Security Printing			78,000
Real Property Rental Income			16,000
Total Printed Products Revenue		$	4,935,000

Three months ended September 30, 2024
Packaging Printing and Fabrication		$	4,773,000
Commercial and Security Printing			55,000
Real Property Rental Income			18,000
Total Printed Products Revenue		$	4,846,000

Nine months ended September 30, 2025
Packaging Printing and Fabrication		$	12,839,000
Commercial and Security Printing			334,000
Real Property Rental Income			48,000
Total Printed Products Revenue		$	13,221,000

Nine months ended September 30, 2024
Packaging Printing and Fabrication		$	11,080,000
Commercial and Security Printing			333,000
Real Property Rental Income			53,000
Total Printed Products Revenue		$	11,466,000

Commercial Lending Revenue Information:

Three months ended September 30, 2025
Net Investment Income		$	7,000
Total Commercial Lending Revenue		$	7,000

Three months ended September 30, 2024
Net Investment Income		$	45,000
Total Commercial Lending Revenue		$	45,000

Nine months ended September 30, 2025
Net investment income		$	37,000
Total Commercial Lending Revenue		$	37,000

Nine months ended September 30, 2024
Net Investment Income		$	192,000
Total Commercial Lending Revenue		$	192,000

Nine months ended September 30, 2024
Retail sales		$	3,000
Total Direct Marketing Revenue		$	3,000

Biotechnology Revenue Information:
Three months ended September 30, 2025
Retail internet sales		$	11,000
Total Biotechnology Revenue		$	11,000

Three months ended September 30, 2024
Retail internet sales		$	1,000
Total Biotechnology Revenue		$	1,000

Nine months ended September 30, 2025
Retail internet sales		$	32,000
Total Biotechnology Revenue		$	32,000

Nine months ended September 30, 2024
Retail internet sales		$	2,000
Total Biotechnology Revenue		$	2,000

Securities Revenue Information:

Three months ended September 30, 2025
Rental income		$	702,000
Commission income		$	737,000
Total Securities Revenue		$	1,439,000

Three months ended September 30, 2024
Rental income		$	478,000
Commission income		$	229,000
Total Securities Revenue		$	707,000

Nine months ended September 30, 2025
Rental income		$	2,099,000
Commission income		$	1,241,000
Total Securities Revenue		$	3,340,000

Nine months ended September 30, 2024
Rental income		$	1,281,000
Commission income		$	737,000
Total Securities Revenue		$	2,018,000

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration